ReviewLeukemia & lymphoma2016
The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.
Review in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 67 citations in OpenAlex.
- Multidrug-Resistant Gram-Negative Bacteremia among Pediatric Oncology Patients with Neutropenic Fever: Associated Risk Factors and Mortality Outcomes.Infection & chemotherapy · 2026Article
- Gram-negative gut colonization in children newly diagnosed with malignancy: microbiology, antimicrobial resistance pattern, and clinical implications.Gut pathogens · 2026Article
- Risk factors for 28-day mortality and pathogen characteristics of septic shock in children: a 10-year retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Clinical characteristics and prognostic impact of Burkholderia cepacia complex colonization and infection in patients with hematologic malignancies.Frontiers in cellular and infection microbiology · 2026Article
- Syndemics of Antimicrobial Resistance: Non-communicable Diseases, Social Deprivation, and the Rise of Multidrug-Resistant Infections.Infectious diseases and therapy · 2025Article
- Ceftazidime-avibactam use in hematology patients: single-center experience.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Multidrug-Resistant Bacteria in Immunocompromised Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- An Emergent Change in Epidemiologic and Microbiological Characteristics of Bloodstream Infections in Adults With Febrile Neutropenia Resulting From Chemotherapy for Acute Leukemia and Lymphoma at Reference Centers in Chile, Ecuador, and Peru.Open forum infectious diseases · 2024Article
- Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.Frontiers in cellular and infection microbiology · 2024Observational
- Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistantAnnals of medicine · 2022Article
- Comparison between hospital- and community-acquired septic shock in children: a single-center retrospective cohort study.World journal of pediatrics : WJP · 2022Article
- Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).Microbiology spectrum · 2022Article
- Factors Associated with Gram-Negative Bacteremia and Mortality in Neutropenic Patients with Hematologic Malignancies in a High-Resistance Setting.Infectious diseases & clinical microbiology · 2022Article
- Optimization of cultural conditions for enhancement of anti-quorum sensing potential in the probiotic strain3 Biotech · 2022Article
- Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.GMS hygiene and infection control · 2022Article
- Genomic Investigation and Successful Containment of an Intermittent Common Source Outbreak of OXA-48-Producing Enterobacter cloacae Related to Hospital Shower Drains.Microbiology spectrum · 2021Article
- Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study).Antimicrobial agents and chemotherapy · 2021Article
- Imaging of abdominal and pelvic infections in the cancer patient.Abdominal radiology (New York) · 2021Review
- Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Prolonged neutropenia and chemotherapy-induced mucositis render patients with hematologic malignancies highly vulnerable to Gram-negative bacteremia. Unfortunately, multidrug-resistant (MDR) Gram-negative bacteria are increasingly encountered globally, and current guidelines for empirical antibiotic coverage in these patients may not adequately treat these bacteria. This expansion of resistance, coupled with traditional culturing techniques requiring 2-4 days for bacterial identification and antimicrobial susceptibility results, have grave implications for these immunocompromised hosts. This review characterizes the epidemiology, risk factors, resistance mechanisms, recommended treatments, and outcomes of the MDR Gram-negative bacteria that commonly cause infections in patients with hematologic malignancies. We also examine the infection prevention strategies in hematology patients, such as infection control practices, antimicrobial stewardship, and targeted decolonization. Finally, we assess the strategies to improve outcomes of the infected patients, including gastrointestinal screening to guide empirical antibiotic therapy, new rapid diagnostic tools for expeditious identification of MDR pathogens, and use of two new antimicrobial agents, ceftolozane/tazobactam and ceftazidime/avibactam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.